<DOC>
	<DOCNO>NCT01335191</DOCNO>
	<brief_summary>This protocol represent third human study TUTI-16 , conduct gather additional safety human immunogenicity ( anti-HIV-1 Tat titer ) data subcutaneously administer TUTI-16 .</brief_summary>
	<brief_title>Clinical Study TUTI-16 Asymptomatic HIV-1 Infected Subjects ( THYMON-11001 )</brief_title>
	<detailed_description>In study , HIV-1 infect subject ART , undetectable HIV-1 viral load , immunize 1mg TUTI-16 placebo randomize double blind fashion ( prime 3 week boost ) . Three week 3 week boost ( week 6 ) ART stop . HIV-1 viral load CD4+ T-cell level determine define interval 54 week ( 48 week Post ART discontinuation ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Males Females Age ≥ 18 ≤ 50 year Screening Body weight 50100 kg ( inclusive ) Screening . HIV1 seropositive subject effective ART &gt; 12 month ( undetectable HIV plasma viremia ) , viral set point ART &gt; 10,000 . CD4+ Tcell count ≥ 500/mm3 . No antiviral drug within 8 week screen . Patients stabilize Aciclovir Valciclovir 6 month may enrol . Karnofsky performance status &gt; 90 % screening . In good health determine medical history , baseline physical examination , vital sign , clinical laboratory test . Subject willing able sign write informed consent prior begin study procedure . Subject willing able follow instruction , comply protocol requirement make require study visit . Females plan become pregnant course study . Females positive pregnancy test Screening study enrollment . Any outof range laboratory value screen review , approve document clinically significant Principal Investigator . Systemic infection vaccination within 6 week prior screen . Live vaccine within 1 year screening . Autoimmune disease ( e.g. , psoriasis , rheumatoid arthritis , etc . ) inflammatory bowel disease confirm clinical history . Positive screen HBV ( HBsAg assay ) HCV ( antibody ELISA ) unless active infection judge elevated alanine aminotransferase ( ALT ) screening . Alanine aminotransferase ( ALT ) upper limit normal screening . Hemoglobin outside laboratory normal range screening . Absolute neutrophil count outside laboratory normal range screening . Platelet count outside laboratory normal range screening . A history significant drug allergy . A general medical psychological condition behavior , include current substance dependence abuse , opinion investigator , might permit subject complete study sign inform consent . Subjects experience acute Herpetic event . Any condition clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen , opinion Principal Investigator would make subject unsuitable study put additional risk . Routine PRN consumption immune suppressive medication subject unable unwilling discontinue study . Inability understand follow study instruction . Participation another investigational drug/vaccine study within 30 day precede first injection investigational agent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>vaccine</keyword>
	<keyword>lipopeptide</keyword>
	<keyword>Tat</keyword>
	<keyword>TUTI-16</keyword>
	<keyword>THYMON</keyword>
</DOC>